title

اثرات Tanezumab بر استئوآرتریت زانو: مروری سیستماتیک و متاآنالیز

نکته سنج, رضا ، نوریان, سید محمدامین ، عموزاده عمرانی, فرزاد (1400) اثرات Tanezumab بر استئوآرتریت زانو: مروری سیستماتیک و متاآنالیز. Journal of Reviews in Medical Sciences ــ 1 (2). ص.ص.1-10. شاپا 2692-4013

متن کامل

[img]
پیش نمایش
متنی - نسخه چاپ شده
684kB

آدرس اینترنتی رسمی : http://jrevmeds.com/index.php/jrms/article/view/31


عنوان انگليسی

Effects of Tanezumab on Osteoarthritis of the Knee: A Systematic Review and Meta-Analysis

خلاصه انگلیسی

Background: Tanezumab is known as a new medical treatment for patients with osteoarthritis (OA) of the knee. We performed this meta-analysis to investigate the efficacy and safety of Tanezumab for treatment of patients with knee OA. Methods: We systematically searched randomized controlled trials from MEDLINE, Scopus, EMBASE, EBSCO, and the Cochrane Central Register of Controlled Trials (CENTRAL). The selected primary outcomes for this study were mean change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain, the WOMAC physical function and patient's global assessment (PGA). Outcomes were reported using the standard mean difference (SMD) or odds ratio (OR) with 95% confidence interval (CI). We evaluated the pooled data using a random and fixed effects models. Results: Of the studies that were found during systematic search, five studies were eligible and were included in this meta-analysis. Compared with the placebo groups, tanezumab showed a significant more reduction in mean of the WOMAC pain (SMD = -0.92, 95% CI -1.47 to -0.37, P=0.001), the WOMAC physical function (SMD = -0.59, 95% CI -0.79 to -0.39, P<0.01), and PGA (SMD = -0.36, 95% CI -0.45 to -0.27, P<0.01). There was no significant difference in serious adverse events (OR = 1.38, 95% CI 0.59 to 3.21, P = 0.48) between the tanezumab and placebo groups. Placebo significantly decreased discontinuations due to adverse events (OR = 0.37, 95% CI 0.21 to 0.64, P = 0.001), abnormal peripheral sensations (OR = 0.32, 95% CI 0.21 to 0.50, P<0.01), and peripheral neuropathy (OR = 0.25, 95% CI 0.13 to 0.48, P<0.01). Conclusion: This meta-analysis showed that Tanezumab can decrease pain and improve function for patients with OA of the knee. However, due to the limited number of studies, this conclusion should be interpreted cautiously and further clinical randomized controlled trials will be required to approve the efficacy and safety of tanezumab for OA of the knee.

نوع سند :مقاله
زبان سند : انگلیسی
نویسنده مسئول :رضا نکته سنج
نویسنده :سید محمدامین نوریان
نویسنده :فرزاد عموزاده عمرانی
ضریب تاثیر و نمایه مجلات:Indexed in: Google Scholar
کلیدواژه ها (انگلیسی):knee, Osteoarthritis, Tanezumab, Systematic review, Meta-analysis
موضوعات :WO جراحی
بخش های دانشگاهی :دانشكده پزشكي > گروه جراحی
کد شناسایی :15898
ارائه شده توسط : دکتر بیتا شهباززادگان
ارائه شده در تاریخ :25 خرداد 1401 09:17
آخرین تغییر :25 خرداد 1401 09:21

فقط پرسنل کتابخانه صفحه کنترل اسناد

Document Downloads

More statistics for this item...